Jussi Rytkonen
Overview
Explore the profile of Jussi Rytkonen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lehtimaki K, Rytkonen J, Pussinen R, Shatillo A, Bragge T, Heikkinen T, et al.
J Physiol
. 2024 Oct;
602(20):5353-5373.
PMID: 39365978
A significant fraction of the popular inbred C57Bl/6J mice show structural and biochemical features of the congenital portosystemic shunt (PSS). How this hepatic abnormality affects physiological and behavioural parameters has...
2.
Johnson T, Brudvig J, Lehtimaki K, Cain J, White K, Bragge T, et al.
Prog Neurobiol
. 2020 Mar;
189:101789.
PMID: 32198061
While research has accelerated the development of new treatments for pediatric neurodegenerative disorders, the ability to demonstrate the long-term efficacy of these therapies has been hindered by the lack of...
3.
Huhtala T, Poutiainen P, Rytkonen J, Lehtimaki K, Parkkari T, Kasanen I, et al.
EJNMMI Radiopharm Chem
. 2019 Oct;
4(1):20.
PMID: 31659519
Purpose: Dopamine receptors are involved in pathophysiology of neuropsychiatric diseases, including Huntington's disease (HD). PET imaging of dopamine D2 receptors (D2R) in HD patients has demonstrated 40% decrease in D2R...
4.
Cui L, Nitzsche F, Pryazhnikov E, Tibeykina M, Tolppanen L, Rytkonen J, et al.
Stroke
. 2017 Sep;
48(10):2895-2900.
PMID: 28916665
Background And Purpose: Very late antigen-4 (integrin α4β1)/vascular cell adhesion molecule-1 mediates leukocyte trafficking and transendothelial migration after stroke. Mesenchymal stem cells (MSCs) typically express integrin β1 but insufficient ITGA4...
5.
Kaasalainen M, Rytkonen J, Makila E, Narvanen A, Salonen J
Langmuir
. 2015 Jan;
31(5):1722-9.
PMID: 25604519
Porous silicon (PSi) nanoparticles' tunable properties are facilitating their use at highly challenging medical tasks such as peptide delivery. Because of many different mechanisms that are affecting the interaction between...
6.
Wang C, Makila E, Bonduelle C, Rytkonen J, Raula J, Almeida S, et al.
ACS Appl Mater Interfaces
. 2014 Dec;
7(3):2006-15.
PMID: 25539741
Porous silicon (PSi) nanomaterials combine a high drug loading capacity and tunable surface chemistry with various surface modifications to meet the requirements for biomedical applications. In this work, alkyne-terminated thermally...
7.
Nakki S, Rytkonen J, Nissinen T, Florea C, Riikonen J, Ek P, et al.
Acta Biomater
. 2014 Dec;
13:207-15.
PMID: 25463492
Nanotechnology has attracted considerable interest in the field of biomedicine, where various nanoparticles (NPs) have been introduced as efficient drug carrier systems. Mesoporous silicon (PSi) is one of the most...
8.
Vlasova M, Rytkonen J, Riikonen J, Tarasova O, Monkare J, Kovalainen M, et al.
Eur J Pharm Sci
. 2014 Jun;
63:96-102.
PMID: 24964293
Intravenously administered nanocarriers are widely studied to improve the delivery of various therapeutic agents. However, recent in vivo studies have demonstrated that intravenously administered nanocarriers that do not contain any...
9.
Rytkonen J, Arukuusk P, Xu W, Kurrikoff K, Langel U, Lehto V, et al.
Mol Pharm
. 2013 Dec;
11(2):382-90.
PMID: 24341621
The largest obstacle to the use of oligonucleotides as therapeutic agents is the delivery of these large and negatively charged biomolecules through cell membranes into intracellular space. Mesoporous silicon (PSi)...
10.
Huhtala T, Weisell J, Rytkonen J, Narvanen A
Methods Mol Biol
. 2013 Oct;
1088:171-83.
PMID: 24146404
The main goal in modern biomedicine is to develop specific diagnostic and therapeutic agents for different diseases. Especially in cancer research tumor targeted molecules are the key factor in the...